Agent Capital

Type

Venture Capital

Status

Active

Location

Waltham, United States

Total investments

36

Average round size

47M

Portfolio companies

24

Rounds per year

5.14

Lead investments

1

Follow on index

0.31

Exits

3

Stages of investment
SeedEarly Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedicalLife SciencePharmaceuticalTherapeuticsBiopharmaEmergency Medicine

Summary

The company was established in North America in United States. The main department of described VC is located in the Cambridge.

Among the most popular fund investment industries, there are Genetics, Health Care. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Orchard Therapeutics, Skyhawk Therapeutics, Skyhawk Therapeutics. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund.

The overall number of key employees were 3.

The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. The real fund results show that this VC is 9 percentage points less often commits exit comparing to other companies. This Agent Capital works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 50 - 100 millions dollars. The top amount of exits for fund were in 2018.

The typical case for the fund is to invest in rounds with 9-10 participants. Despite the Agent Capital, startups are often financed by Tim Disney, The Duke of Bedford, F-Prime Capital. The meaningful sponsors for the fund in investment in the same round are Alexandria Venture Investments, Cowen Healthcare Investments, Wellington Partners. In the next rounds fund is usually obtained by Venrock, Tim Disney, The Duke of Bedford.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesHealthcareMedtech
Stage focus
GeneralistPre-SeedSeedSeries ASeries B Show 1 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
36
Lead investments
1
Exits
3
Rounds per year
5.14
Follow on index
0.31
Investments by industry
  • Biotechnology (30)
  • Health Care (22)
  • Therapeutics (17)
  • Medical (11)
  • Life Science (9)
  • Show 20 more
Investments by region
  • United States (31)
  • United Kingdom (2)
Peak activity year
2018

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
6
Avg. valuation at time of investment
3M
Group Appearance index
0.94
Strategy success index
0.50

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
āshibio 20 Jun 2024 Early Stage Venture 40M
Carisma Therapeutics 01 Mar 2021 Biotechnology, Health Care, Medical, Life Science, Therapeutics Early Stage Venture 12M United States, Pennsylvania, Philadelphia

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.